“Dexcom had an incredible year in 2023 with the largest expansion of coverage in our company’s history, a successful rollout of Dexcom G7 in the U.S. and expansion of G7 to more than 15 international markets, and an acceleration in our revenue growth,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We plan to continue this momentum in 2024 and further expand our addressable market with the expected launch of our first product for people who do not use insulin.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- DexCom price target raised to $150 from $125 at BTIG
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/2/2024
- DexCom participates in a conference call with William Blair
- William Blair says buy these stocks for 2024
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
